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Abstract 
AIM: To analyse the characteristics, and analyse the impact of pharmacist intervention on quality of life (QOL) 
outpatients with type 2 diabetes mellitus (T2DM). 
METHODS: This six-month analytical cohort study was conducted by assessing the patients’ characteristics and 
their quality of life by distributing a questionnaire, and the 36-Item short form instrument to the patients with T2DM 
(n = 45) admitted to the Tertiary hospital in Tebing Tinggi. Patients who had mental disorders, HIV-AIDS, liver 
disease, stage 4 chronic kidney disease, and pregnant women were excluded from the study. The patients’ quality 
of life was measured before and after interventions and analysed using the paired t-test. All analyses were 
performed using the Statistical Package for the Social Sciences (SPSS, version 22, Chicago, IL, USA) (p < 0.05 
was considered significant).  
RESULTS: The mean age of the patients was 61.96 ± 6.45 (years). Most (66.7%) of them were females. The 
mean QOL (in the score) of the patients: before the intervention, 61.07 ± 15.13; after the intervention, 70.15 ± 
14.23, there was a significant difference between groups with and without interventions, p < 0.001.  
CONCLUSION: Active contribution of pharmacists in the management of T2DM patients is urgent and important 
to improve the patients’ QOL. 
 
 
 
 
 
 
 
Introduction 
 
Diabetes mellitus (DM) is a serious and 
chronic disease that occurs either when the pancreas 
does not produce enough insulin, or when the body 
cannot effectively use the insulin produced. The global 
prevalence of diabetes among adult has increased 
from 4.7% in 1980 to 8.5% in 2014. A more recent 
study indicated that as many as 422 million people 
live with diabetes in 2016 [1]. In Indonesia, there were 
over 10,276,100 diabetes cases (6.7% of total adult 
population) in 2017 [2].  
Raise in blood glucose level can lead to many 
serious complications such. Type 2 diabetes called 
non-insulin-dependent or adult-onset diabetes results 
from the ineffective use of insulin by the body. When 
diabetes is not well managed, various complications 
will develop including diabetic retinopathy, diabetic 
nephropathy, diabetic neuropathy, and heart failure 
that affect the patients’ quality of life (QOL). These 
conditions require complex management and multiple 
drug therapy, which in turn, may result in increased 
risk for the patients to experience drug-related 
problems (DRPs), readmissions, treatment costs, 
morbidity, and mortality [3]. The disease will 
accompany the patient’s lifetime and worsen over time 
if not treated properly [4]. Many complicated factors 
are also associated with the successfulness of 
treatment of patients with T2DM including age, 
gender, educational level, socioeconomic status, the 
disease duration, multiple long-term complications of 
DM, the ability of the patients to cope with her or his 
diseases, adherence to the provided medications, and 
the provided healthcare. These issues are the 
challenges of the healthcare systems in the 
international as well as a national level [5], [6]. 
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 Management of the T2DM patients requires 
the active involvement of many healthcare providers, 
including a pharmacist. Pharmacists specialised in 
this growing chronic condition can have a significant 
and positive impact on the QOL of the patients as well 
as healthcare systems [7]. Awareness of healthcare 
providers on the need to assess and monitor the 
patients’ QOLs as an important outcome in diabetes 
management has increased. The QOL is an important 
outcome since it influences the patient’s self-care 
activities which can have a positive contribution to 
diabetes control [8].  
 Many pharmacist interventions programs 
have been established in various countries to 
enhance clinical outcomes and QOL. These programs 
were implemented by pharmacists, with the 
cooperation of physicians and other health care 
providers. Pharmacist interventions and the expanded 
role of pharmacists are associated with many positive 
diabetes-related outcomes, including improved clinical 
measures [9], improved patient and provider 
satisfaction [10], [11], and reduced the treatment cost 
[10], [12]. Subsequently, the pharmacist can 
contribute to an improvement in the QOL of patients 
with diabetes by informing and educating patients, 
answering their questions, and, at the same time, 
monitoring the outcomes of their treatment [13]. 
 About the problems previously described, 
the present study was undertaken to analyse the 
impact of pharmacist intervention on QOLs of T2DM 
patients before and after educations. 
 
 
Material and Methods 
 
This six-month analytical cohort study was 
undertaken by assessing the patients’ characteristics 
and their QOLs by distributing a self-designed 
questionnaire, and the 36-Item Short Form Survey 
(SF36) instrument [14] to the patients with T2DM (n = 
45) admitted to a Tertiary hospital in Tebing Tinggi, 
Indonesia. The inclusion criteria were T2DM patients 
with age of 18 years or older and agreed to sign the 
informed consent. Patients had mental disorders, HIV-
AIDS, liver disease, stage 4 of chronic kidney disease 
and pregnant women were excluded from the study. 
The study was approved by the Health Research 
Ethical Committee, Faculty of Medicine, University of 
Sumatera Utara, Indonesia. The required data were 
assessed from the three-month periods of admission 
with and without interventions. Thus, the overall study 
period was six months. The education provided to the 
patients comprised lifestyle changes (physical activity 
and eating habit), adherence to the prescribed 
medications, and how to use and to store the 
medications. The patients’ characteristics assessed in 
this study comprised gender, age, education, 
occupation, duration of the disease, and utilisation of 
antihyperglycemic drugs from the patients’ medical 
records. The QOL of each of the patients was 
assessed using the SF-36 questionnaire filled out by 
each of the patients in categories good, fair, bad and 
also divided at groups before and after the 
intervention to obtain their QOLs under the direction of 
the researchers.  
At the beginning of the last three-month 
period of the study, leaflet contained materials 
regarding “Living healthy with diabetes”, the guide 
suggested by American Diabetes Associaton [15] 
were also provided to the patients. The leaflet consists 
of how to take care of diabetes, healthy foods, 
physical activity, and medicine for diabetes. The 
researchers followed up the patients’ outcome every 
admission (10 day period). Since the outpatients were 
insured by Indonesia Universal Health Coverage, they 
were asked to admit to the hospital every 10 days. At 
this time the treatment outcomes and laboratory 
examination were done. The patients’ QOLs were 
recorded during each visit. Data required to analyse 
the patients’ QOLs were collected at the last visit of 
each patient in each of the three months.  
The patients’ characteristics and the 
prescribed antihyperglycemic drugs provided to them 
were descriptively analysed. The significance of 
pharmacist intervention was analysed by comparing 
their QOLs before and after educations using the 
paired t-test. All analyses were performed using the 
Statistical Package for the Social Sciences (SPSS, 
version 22, Chicago, IL, USA) (p-value < 0.05 was 
considered significant). 
 
 
Results 
 
In this study, the target population obtained 
during the study period were 130 patients. Of these 
population, there were only 45 patients fulfilled the 
inclusion criteria; then these patients were used as a 
sample. Characteristics of the patients with T2DM are 
shown in Table 1.  
Table 1:  Characteristics of the patients with T2DM (n = 45) 
  
Percentage (%) 
Age (Years) 46-55 13 
 
56-65 65 
 
> 65 22 
Gender Female 67 
 
Male 33 
Education University 38 
  Senior high school 29 
 
Primary school 18 
 
Junior high school 15 
Duration of the desease (years)  > 5 56 
  > 1-5 31 
  0-1 13 
 
The mean age of the T2DM patients was 
61.69 ± 6.45 (years). By age, more than half (65%) of 
them were in the age range of 56-65 years, twenty-
two per cent of them were above 65 years old, and 
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thirteen per cent were in the age range of 46-55 
years. Among the 45 patients, most (67%) of them 
were females. The T2DM patients had a different level 
of education. Most (38%) of them graduated from 
University, twenty-ninth per cent of them graduated 
from senior high schools. Less than a quarter (18%) of 
the T2DM patients graduated from primary school, 
and twenty per cent of them graduated from junior 
high school. 
By duration of the disease, it was found that 
most of the patients (56%) have suffered from 
diabetes for more than 6 years. Nearly one third 
(31%) of them had suffered from diabetes for 1-5 
years. Only thirteen per cent of them had suffered 
from the disease for 0-1 year.  
The utilisation of antihyperglycemic drugs in 
the management of patients with T2DM before and 
after pharmacist intervention is listed in Table 2. As 
shown in Table 2, the four antihyperglycemic drugs 
widely provided to the patients with T2DM before 
pharmacist intervention in decreasing order were 
metformin 500 mg (47.3%), glimepiride 2 mg (28.4%), 
gliclazide (10.5%), and glimepiride 4 mg (4,2%). The 
same results were obtained in the group with 
intervention. 
Table 2:  Utilization of antihyperglycemic drugs in the 
management of patients with T2DM (n = 45) 
Drug utilised The proportion of the patients (%) 
Before Pharmacist 
educations 
After pharmacist 
educations 
Metformin 500 mg 47.3 46.1 
Glimepiride 2 mg 28.4 26.8 
Gliclazide 10.5 11.9 
Glimepiride 4 mg 4.2 7.5 
Acarbose 50 mg 3.4 0 
Glimepiride 3 mg 2.6 3.6 
Glimepiride 1 mg 1.6 2.5 
Insulin glulisine 1.5 1.0 
Insulin glargine 0.4 0.5 
Insulin lispro 0 0.1 
 
The least prescribed antidiabetic drugs in the 
group before intervention were acarbose 50 mg 
(3.4%t), glimepiride 3 mg (2.6%), glimepiride 1 mg 
(1.6%), Apidra (1.5%), and Lantus (0.4%). 
Subsequently, the least frequently prescribed 
antihyperglycemic drugs provided to the patients with 
T2DM after pharmacist intervention in decreasing 
order were glimepiride 3 mg (3.6%), glimepiride 1 mg 
(2.5%), insulin glulisine (1%t), insulin glargine (0.5%), 
and insulin lispro (0.1%). 
The QOLs of the patients with T2DM before 
and after pharmacist interventions is demonstrated in 
Table 3. There were only 36% of the patients with 
T2DM had good QOLs in the group before the 
intervention. However, the proportion of patients with 
a good category in the group with intervention has 
increased to 58%. Similarly, as much as twenty per 
cent of the patients had fair QOLs in the group before 
pharmacist intervention. The proportion of T2DM 
patients with fair category has increased to twenty-
four per cent. Nearly half (44%) of the T2DM patients 
had bad QOLs in the group before the intervention 
while only eighteen per cent of the patients had bad 
QOLs in the group after intervention. 
Table 3:  The QOL of patients with T2DM (n = 45) before and 
after pharmacist education 
  
 Category 
Before pharmacist intervention After pharmacist intervention 
Number of 
patients 
Percentage (%) Number of 
patients 
Percentage 
(%) 
Good (> 70) 16 36 26 58 
Fair (60-70) 9 20 11 24 
Bad (0-60) 20 44 8 18 
 
Overall, the mean value of the patients’ QOLs 
before pharmacist intervention was 61.08 ± 15.13. 
While the mean value of the QOL of the patients with 
T2DM after pharmacist intervention has improved to 
70.15 ± 14.23. There was a significant difference 
between the patients’ QOLs before the intervention 
and those with the intervention (p-value < 0.001). 
 
 
Discussion 
 
The present study found that the mean age of 
the T2DM patients was 61.69 ± 6.45 (years). Most of 
them (67%) were females. A study on T2DM patients 
conducted in Indonesia also revealed that most (66%) 
of T2DM patients were females [16]. Previous studies 
undertaken in India in the rural areas of 
Kumarapalayam and Alimosho general hospital, 
Nigeria revealed that the proportion of female T2DM 
patients were 60% and 72,4%, respectively [17], [18]. 
On the other hand, another study conducted in 2016 
revealed that there was no significant difference in the 
prevalence of the disease between male and female 
[19]. It has been proved that the body mass index is 
an important contributor to the increase in the 
prevalence of diabetes [20]. Lastly, a large-scale 
prospective cohort study was undertaken in Spain 
also revealed that the incidence of T2DM increased 
with the increasing incidence of obesity [21].  
By age, most of the T2DM patients were at 
the age range of 56-65 years and older. There was a 
similar study conducted in Helvetia primary health 
centre in Medan, Indonesia [16], in the rural areas of 
Kumarapalayam, India [17] and Alimosho general 
hospital, Nigeria [18]. This finding also supported the 
statement of the American Diabetes Association, that 
people at the age of 45 years or older are more prone 
to develop T2DM [22]. Ageing affects the pancreatic β 
cell sensitivity to glucose and delays the mediation of 
glucose uptake by insulin into the cells. Thus, the 
incidence of T2DM patients was high in older age [21]. 
The most frequently antihyperglycemic drugs 
provided to the patients with T2DM before and after 
pharmacist educations was metformin. According to 
the American Diabetes Association, metformin 
monotherapy should be started for a person initially 
diagnosed as having T2DM unless there are 
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contraindications [21]. This drug as first-line therapy 
has more beneficial effects on A1c, obese person, 
and cardiovascular mortality event if compared to 
sulfonylurea. Provision of metformin may be safe in 
patients with estimated glomerular filtration rate 
(eGFR) of 30 mL/min/1.73 m
2
. The use of metformin 
as first-line therapy was supported by findings from a 
large meta-analysis [23], [24].  
The next three antidiabetic drugs provided to 
the patients in decreasing order were glimepiride 2 
mg, glucodex and glimepiride 4 mg. These drugs are 
included in sulfonylurea class whose mechanism of 
action to increase insulin secretion by pancreatic beta 
cells to have a hypoglycemic effect. A sulfonylurea is 
an option for adult patients with DM with normal 
weight who have never experienced ketoacidosis. 
This study is the same as with another study has been 
conducted, A previous study conducted in a tertiary 
care teaching hospital in Eastern India indicated that 
the most widely used antihyperglycemic agent was 
biguanide followed by sulfonylureas [25]. Another 
study proved that the most widely used 
antihyperglycemic agent was metformin followed by 
the sulfonylurea class of drugs [26].  
Quality of life is the main health outcome in 
the treatment of T2DM [23]. Education and 
behavioural changes are required to manage the 
disease conditions properly and to improve the 
patients’ QOLs. Lifestyle changes must incorporate 
careful dietary planning, appropriate use of 
antidiabetic drugs, and home blood sugar monitoring 
techniques for all DM patients [23]. In health care 
practice, therapeutic outcomes directly influence the 
physical, psychological and social domains of health. 
These factors will affect the overall QOL [27].  
The present study proved that pharmacist 
intervention significantly improve QOLs of T2DM 
patients. Similar studies have been conducted by 
researchers in several countries. It has also been 
confirmed that clinical pharmacist mediated 
intervention on drugs, disease, diet, exercise, lifestyle 
modifications, and self-care practices in the 
management of diabetes has significant improvement 
of QOLs of patients with T2DM [27]. Additionally, a 
study undertaken toward T2DM patients in a military 
hospital, Myanmar proved that pharmacist intervention 
had a significant mean of QOL of the patients 
compared to those without intervention, p < 0.001. 
The researchers also reported that blood glucose 
concentration, body mass index, and waist 
circumference were significantly improved (p < 0.05) 
[28]. Eikenhorst reported in their systematic review 
and meta-analysis recruited from twenty-four studies 
from electronic databases from 2004 through 2017 
revealed that pharmacist led-self-management 
interventions improved HbA1c value in the 
management of diabetes patients [29].  
The present finding proved that enough 
provision of information related to the management of 
diabetes improved the QOLs of DM patients. 
Continuous education programs and counselling 
should be conducted for diabetic patients to 
emphasise and re-emphasize the importance of risk 
factor, prevention, medication, and behavioural 
changes [30]. The pharmacists’ expanded roles in the 
healthcare sectors should be implemented to improve 
outcomes of the management of T2DM patients [31].  
In conclusion, the present study highlighted 
that involvement of pharmacists in the management of 
patients with T2DM significantly improved QOLs of the 
patients. Metformin 500 mg was the most widely 
prescribed antihyperglycemic drug to the patients with 
T2DM. Improvement of the patients’ knowledge about 
their disease, diet control, life style modification, and 
appropriate use of medications through education and 
medication counseling by clinical pharmacists have 
positive effects on the patients’ clinical outcome. 
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